Director/PDMR Shareholding
GlaxoSmithKline PLC
21 February 2008
Notification of Transactions of Directors and
Persons Discharging Managerial Responsibility
Vesting of awards made under GlaxoSmithKline's share plans in 2004
This notification, prepared in accordance with Disclosure and Transparency Rule
3.1.4R(1)(a), sets out the vesting of share awards made in 2004, under the
GlaxoSmithKline Performance Share Plan.
Performance Share Plan
The three-year performance period for the GlaxoSmithKline Performance Share Plan
(PSP) awards made in 2004, which commenced on 1 January 2005, came to an end on
31 December 2007.
The Remuneration Committee of the Board of GlaxoSmithKline plc (GSK) considered
the performance achieved in respect of the PSP awards and determined that the
PSP awards granted in 2004 vested as set out in the table below. The vesting of
these awards was subject to the Company's relative Total Shareholder Return
(TSR) performance for the individuals who were Executive Directors or Corporate
Executive Team (CET) members at the time the awards were made. For other
participants, the vesting of the awards was subject in part to TSR and in part
to the Company's Earnings per Share (EPS) growth over the performance period.
The following Executive Directors and CET members, who are all Persons
Discharging Managerial Responsibility (PDMRs), have received the following final
awards in respect of the awards made in 2004. The unvested balance of each award
has lapsed.
Number of Shares/ADSs vesting
Shares ADSs
Dr JP Garnier* 86,327
Mr A P Witty* 33,272
Mr R M Bondy 33,272
Mr J M Clarke 20,687
Mr M Dunoyer 12,531
Mr E J Gray 9,177
Mr J S Heslop* 6,698
Mr D Learmouth 4,332
Dr M Slaoui* 9,177
Dr R G Greig** 10,791
Mr W C Louv 4,056
Mr D J Phelan 16,618
Mr D Pulman 10,791
Mr D M Stout 31,941
Mr C Viehbacher* 16,618
* denotes an Executive Director
** deferred until retirement
Share Option Plan
The three-year performance period for the GlaxoSmithKline Share Option Plan
(SOP) awards made to appointed CET members in 2004, at an option price of £11.23
(or US$43.730 in the case of ADSs), which commenced on 1 January 2005, came to
an end on 31 December 2007. The performance conditions for this grant were met.
The Remuneration Committee of the Board of GSK therefore confirmed that they
were exercisable in full.
Number of Shares/ADSs exercisable
Shares ADSs
Dr JP Garnier* 460,000
Mr A P Witty* 177,500
Mr R M Bondy 177,500
Mr M Dunoyer 70,000
Mr J S Heslop* 62,250
Dr R G Greig 57,500
Mr D J Phelan 88,750
Mr D Pulman 57,500
Mr D M Stout 170,000
Mr C Viehbacher* 88,750
* denotes an Executive Director
The Company, Directors, and Persons Discharging Managerial Responsibility were
advised of these transactions on 21 February 2008.
S M Bicknell
Company Secretary
21 February 2008
Enquiries:
UK Media enquiries: Philip Thomson (020) 8047 5502
Alice Hunt (020) 8047 5502
Gwenan White (020) 8047 5502
US Media enquiries: Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564
Sally Ferguson (020) 8047 5543
Gary Davies (020) 8047 5503
US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
This information is provided by RNS
The company news service from the London Stock Exchange
Latest directors dealings
- 7 hours ago Savannah Energy
- 8 hours ago Buccaneer Energy PLC
- 8 hours ago Savannah Energy
- 8 hours ago Carclo
- 9 hours ago Schroder Japan Growth Fund